Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Roflumilast for treating chronic obstructive pulmonary disease (review of technology appraisal guidance 244) [ID984]

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Company • AstraZeneca UK (roflumilast) Patient/carer groups • Action on Smoking and Health (ASH) • British Lung Foundation • Muslim Council of Britain • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance Professional groups • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Thoracic Society • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • United Kingdom Clinical Pharmacy Association Others • Department of Health • NHS England • Rhondda Cynon Taff LHB • Trafford Healthcare NHS Trust • Welsh Government	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Comparator companies • AstraZeneca UK (aclidinium, aclidinium/formoterol, formoterol, formoterol/budesonide,) • Boehringer Ingelheim (olodaterol, olodaterol/tiotropium, tiotropium) • Chiesi (formoterol, formoterol/budesonide) • GlaxoSmithKline (aclidinium, fluticasone/vilanterol, salmeterol, salmeterol/fluticasone, umeclidinium, umeclidinium/vilanterol) • Meda Pharmaceuticals (theophylline) • Merck Serono (theophylline)

Appendix C

Consultees	Commentators (no right to submit or appeal)
	• Mylan (salmeterol/fluticasone) • Napp Pharmaceuticals (theophylline, formoterol/fluticasone) • Novartis Pharmaceuticals (formoterol, glycopyrronium, indacterol, indacterol/glycopyrronium) • Orion Pharma (UK) (formoterol) • Sandoz (salmeterol/fluticasone) • Teva Pharma (formoterol/budesonide, salmeterol) <u>Relevant research groups</u> • British Association for Lung Research • Cochrane Airways Group • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Aging and Ethnicity <u>Associated Guideline groups</u> • National Clinical Guidelines Centre <u>Associated Public Health groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees
Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators
Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)
An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.